应用SELDI—TOF—MS技术分析多发性骨髓瘤患者血清差异表达蛋白

目的研究多发性骨髓瘤患者血清蛋白质谱的变化，从而筛选出特异性蛋白标志物。方法利用CM10蛋白芯片和SELDI-TOF—MS技术对30例初诊为多发性骨髓瘤的患者和33例健康人的血清蛋白进行分析。获得的蛋白质谱图采用Ciphergen公司的BiomarkerWizard软件分析。结果通过对多发性骨髓瘤患者血清与健康人血清蛋白质谱图分析发现有30个蛋白峰表达量有明显差异（P〈0．05），与健康对照组相比，10个蛋白峰表达上调，20个蛋白峰表达下调，质荷比为3472．79、7778．39、4093．01、4971．15、5343．98的蛋白更具意义。结论结果表明通过多发性骨髓瘤患者与健康对照血清蛋白质谱的比较，有助于筛选得到多发性骨髓瘤的特异性标志物。

Detection of serum differential expression protein by SELDI - TOF - MS technology in the patients with multiple myeloma

Objective To analyze differential expression protein in the patients with multiple myeloma by proteomie technology. Methods Serum protein from 30 patients with multiple myeloma at preliminary diagnosis （ MM group） and 33 healthy people control group were analyzed by CM10 proteinchip array and surface - enhanced laser desorption - ionization time - of - flight mass spectrometry （ SELDI - TOF - MS ）. Ciphergen Biomarker wizard soft- ware was used to identify proteomic features. Results The analysis of the protein map showed, there was siginificant difference between two groups （ P 〈 O. 05 ） in 30 protein peaks. Compared with the control group, 10 protein peaks were up - regulated expression and 20 prtotein peaks were down - regulated expression in MM group. Five prtotein peaks （3472. 79,7778. 39,4093. 01 、 4971.15 , 5343. 98） were of more significance. Conclusion The comparison between the patients with multiple myeloma and healthy people in the serum protein is helpful to screen serum specific markers of multiple myeloma.